International Journal of Drug Delivery Technology

About International Journal of Drug Delivery Technology

International Journal of Drug Delivery Technology — Journal Profile

The International Journal of Drug Delivery Technology (IJDDT) is a peer-reviewed journal of pharmaceutics published from India, carrying the ISSN 0975-4415 and devoted to the science of getting medicines into the body: controlled and targeted release, nanoparticle and transdermal carriers, biopharmaceutics, pharmacokinetics and the formulation technologies that connect them. Its own site at ijddt.com presents an archive running from volume 1 to volume 16, with the regular quarterly issues of its early volumes now supplemented by a very large programme of special issues in the recent ones. SCImago's record names its publisher as Dr. Yashwant Research Labs Pvt. Ltd., while the journal's own site carries the imprint of the International Society for Science and Nature — a discrepancy this profile reports openly and flags for the corrections pass, because a reader is entitled to know which imprint stands behind a journal, and here the two authoritative-looking sources do not agree.

This profile rests on sources checked directly for this record: the journal's own site, including its author instructions, submission pages and archive; SCImago-derived listings of its coverage and standing; and the OpenAlex source record resolved from the journal's ISSN. A foreground query of the DOAJ search API by the journal's ISSN returned no listing at checking time, so no DOAJ listing is claimed. Fees and other details that could not be verified are reported as unverified.

Identity, Ownership and History

The journal's bibliographic identity is stable even where its imprint is not. Its ISSN, 0975-4415, is the one identifier every source agrees on: the journal's own masthead prints it, SCImago records it, and OpenAlex resolves it to a single source record (S4210211336) under the journal's full name, with the standard abbreviation Int. J. Drug Deliv. Technol. Its coverage history in SCImago-derived listings runs 2011–2012 and 2014 onward — this directory's stored record gives the span as 2011–2012, 2014–2026 — and the journal's own archive fills in the human shape of that history: four issues a year through volumes 1 to 15, then a sixteenth volume (2026) whose listing on the site runs to regular issues numbered into the seventies of supplementary parts (issues labelled 1s through 100s appear in the archive menu). However one reads that expansion, the journal today publishes at a scale far beyond its quarterly origins, and its archive is correspondingly one of the largest bodies of Indian pharmaceutics writing in its niche.

On ownership, the record must be stated exactly as found. SCImago-derived listings — which rest on the Scopus source data — name the publisher as Dr. Yashwant Research Labs Pvt. Ltd., an Indian company, and give the journal's country as India. The journal's own site, fetched directly for this profile, states in its footer that the publication is licensed under a Creative Commons licence and "Published by International Society for Science and Nature", and its submission pages give editorial contact addresses at the journal's own domain and at Gmail. Both statements are reported here because both are part of the verifiable record; which body currently holds the publisher's role is a question the corrections pass should settle with the journal. The journal also states on its own site that it is a member of Crossref, and that it appears in the UGC-approved list of journals used for career-advancement purposes in Indian academia — claims made by the journal about itself, reported as such.

Scope and Subject Coverage

The journal's scope is pharmaceutics with delivery at its centre. Its subject description, as carried in publisher-side listings, covers the design, development and evaluation of innovative drug-delivery systems — controlled-release formulations, nanotechnology-based carriers, transdermal systems and drug-targeting mechanisms — together with biopharmaceutics, pharmacokinetics, pharmaceutical biotechnology, and the computational and analytical methods used in formulation and delivery. OpenAlex's topic profile for the source tells the same story from the citation side: its leading topics are advanced drug-delivery systems, drug solubility and delivery systems, transdermal delivery, and nanoparticle-based delivery, with medicinal-plant research also prominent — a reflection of the large volume of phytopharmaceutical formulation work the journal carries from Indian pharmacy institutions.

In practice the journal functions as a broad church for Indian pharmaceutical sciences. Its pages carry formulation-and-evaluation studies of tablets, gels, patches, emulsions and nanoparticle systems; solubility- and bioavailability-enhancement work, a genre the journal has published for a decade, in which nanosuspensions, liposomes, niosomes, solid lipid nanoparticles and cyclodextrin complexes are marshalled against poorly soluble drugs; analytical method-development and validation papers; pharmacokinetic and pharmacodynamic studies; and a steady stream of reviews surveying delivery strategies for particular drug classes and diseases. The centre of gravity is the bench formulation laboratory of the Indian pharmacy college — the institution that trains much of the country's pharmaceutical workforce — and the journal's contents are best understood as that community's research diary: pragmatic, method-heavy and oriented to results that can be reproduced with the equipment a teaching institution actually has.

What Appears in Its Pages

The journal's author instructions define its article types precisely, and they are quoted here because they are the journal's own rules. It publishes reviews — comprehensive and short — original research papers, and technical notes. Original research papers must present unpublished results in sufficient detail to ensure the reproducibility of the experiments described, and must constitute a significant contribution to knowledge. Technical notes contain new, important information for which urgent publication is desirable, require an explanatory statement of the urgency in the cover letter, and in general should not exceed four printed pages. Review articles should be concise and critical surveys of novel accomplishments in the author's field, bringing up the most important current topics or presenting interpretative and critical accounts rather than simple compilations, and should run to around fifteen pages. Manuscripts are reviewed by members of the editorial board, whose opinions form the basis of the editor's final decision. The instructions further recommend that manuscripts receive an English-language check by a competent speaker before submission, warning that failure to follow the guidelines may delay or lead to rejection — practical advice that the journal's international contributors, in particular, should take seriously.

Editorial Process and Peer Review

The journal describes a conventional board-based review: submissions are sent to editorial-board reviewers, and the editor decides on their opinions. Its submission pages add one concrete operational figure: after a manuscript number is allotted — itself issued after a manual verification by the editorial board — the peer-review process may take from seven to twenty-one days, with the decision communicated as soon as the process completes. Queries about a manuscript's status, the journal instructs, should be made as a reply to the message that allotted the manuscript number, since each manuscript is allotted to an independent editor who alone holds its position. Submissions are accepted through both an online form and the journal's official email addresses, a dual route the site documents explicitly, with an automatic acknowledgement promised within an hour and a request to enquire if none arrives within twenty-four hours. The names of the current editor-in-chief and board could not be verified from the sources fetched for this profile and are not stated here; the journal's site carries its editorial-board pages for authors who need them.

Metrics and Citation Record

The journal's metrics are reported here with their sources, because the sources disagree in instructive ways. OpenAlex, resolving the source from its ISSN at checking time, recorded 13,368 works and 2,568 citations, with an h-index of 17 and an i10-index of 49, and first works in 2009; that works count is OpenAlex's own aggregation at checking time and reflects the journal's very large recent output, including its special-issue programme. SCImago-derived listings give a smaller, Scopus-bounded picture: an h-index reported as 13 in one current listing and 18 in another compiled a year earlier, an SJR of 0.143 in the more recent of them, a third-quartile placing in Pharmaceutical Science, and 201 citations received in the three years preceding 2022 in the older snapshot. This directory's stored record carried an h-index of 21. Three different h-indices from three different databases is not an error to be resolved by picking the largest: each database counts a different citing literature, and the divergence itself is the honest finding. What all sources agree on is the shape of the journal: a high-volume, nationally rooted pharmaceutics title whose citation footprint is modest relative to its output, and whose role is to give a large community of pharmacy researchers a indexed, citable home rather than to compete with the field's international leaders.

Indexing and Discoverability

The journal is indexed in Scopus, as its SCImago record and its own site's statements attest, and it is a member of Crossref, so its articles carry registered DOIs. Its site also presents it as appearing in the UGC-approved list of journals — a listing of direct practical importance to its core Indian academic authorship, for whom UGC recognition governs the career value of a publication. Against that, a foreground query of the DOAJ search API by ISSN 0975-4415 returned no listing at checking time, and OpenAlex likewise marks the source as not in DOAJ, so no DOAJ listing is claimed in this profile despite the journal's open readability. Authors whose institutions require a specific index should verify the journal's current standing in that index at the time of submission; index lists change, and this profile's checks are dated to its writing.

Open Access, Licensing and Fees

The journal's site states that the publication is licensed under a Creative Commons licence, and its articles are openly readable through its archive; publisher-side listings describe it as an open-access journal. The exact licence variant is stated on the journal's site in general terms rather than pinned to a specific Creative Commons deed in the pages fetched, so this profile does not assert a variant. Whether the journal charges authors — submission fees, processing charges or page charges — could not be verified from the sources fetched for this profile, and no figure is stated. Given the journal's scale and the prevalence of charges in its segment of Indian academic publishing, prospective authors should ask the editorial office directly, in writing, before submitting, and should confirm the total payable before accepting any offer of publication.

How to Submit

Submissions go through the journal's own site at ijddt.com, by its online form and — as the site instructs, using both routes — by its official email addresses, which the site prints on its submission pages. Before submitting, an author should do five things. First, fit the paper to the journal's declared types: a full original-research paper with reproducible methods, a technical note of at most four printed pages with a stated case for urgency, or a critical review of around fifteen pages. Second, have the English checked, as the journal itself recommends. Third, state the delivery problem the formulation solves — the solubility, stability, targeting or adherence failure — and report the characterisation that proves the solution: particle size, entrapment, release profile, stability data. Fourth, note the journal's stated review rhythm, seven to twenty-one days after a manuscript number is allotted, and keep the allotment message, since status queries must ride on it. Fifth, verify the current publisher imprint, charges and board from the journal's site at the time of submission, for the reasons this profile has given.

Similar Journals

Authors weighing IJDDT against its neighbours should compare like with like. The Journal of Advanced Pharmaceutical Technology and Research and the Journal of Applied Pharmaceutical Sciences (post 441946 in this directory, direct-fetched during this record's twin check and carrying different identifiers) serve overlapping Indian and international pharmaceutics readerships at similar quartiles. Drug Development and Industrial Pharmacy and the AAPS journals sit higher in the field's hierarchy for delivery research with international ambitions, while the many national pharmacy journals of Indonesia, Iraq and Egypt that surfaced in this record's twin-check searches serve their own national communities as IJDDT serves India's. The journal's true peer set is the Scopus-indexed, UGC-recognised Indian pharmaceutics titles through which the country's pharmacy colleges publish, and within that set its distinguishing marks are its delivery-technology title and its exceptionally large recent volume.

Strengths, Limits and Fit

The journal's strengths are accessibility, fit and scale. It is indexed in Scopus and recognised in the UGC framework its core authors work under; its scope names exactly the work Indian pharmaceutics laboratories do; its stated review timetable is short; and its archive gives a new paper a large, topically dense neighbourhood to be read in. For a formulation scientist in an Indian pharmacy institution with a sound, reproducible study, it is a realistic and career-legible home.

Its limits should be weighed with equal clarity. Its imprint is stated inconsistently between its own site and the Scopus-derived record, which the corrections pass should resolve. It has no DOAJ listing that could be confirmed. Its citation metrics are modest and diverge between databases, and its very large special-issue volume means an author's paper shares its year with thousands of others. None of these is a reason to dismiss the journal; all of them are reasons to submit with eyes open, having verified the operational facts at the time of submission.

Frequently Asked Questions

What is the ISSN of the International Journal of Drug Delivery Technology? 0975-4415 — the single ISSN on which the journal's own masthead, SCImago and OpenAlex all agree.

Who publishes it? The record is inconsistent: SCImago-derived listings name Dr. Yashwant Research Labs Pvt. Ltd., while the journal's own site carries the imprint of the International Society for Science and Nature. The discrepancy is flagged for the corrections pass.

Is it peer-reviewed? Yes. Its instructions state that manuscripts are reviewed by members of the editorial board, whose opinions form the basis of the editor's decision, with a stated review period of seven to twenty-one days after a manuscript number is allotted.

What are its metrics? OpenAlex recorded 13,368 works, 2,568 citations and an h-index of 17 at checking time; SCImago-derived listings give h-index values of 13 to 18 and an SJR of 0.143, with a third-quartile placing in Pharmaceutical Science.

Is it in DOAJ? No listing was returned by a foreground query of the DOAJ search API at checking time, and none is claimed.

Does it charge authors? Author charges could not be verified from the sources checked; ask the editorial office in writing before submitting.

Key Facts at a Glance

Title: International Journal of Drug Delivery Technology (IJDDT). ISSN 0975-4415. Country: India. Publisher: named as Dr. Yashwant Research Labs Pvt. Ltd. in SCImago-derived listings; the journal's site carries the imprint of the International Society for Science and Nature (discrepancy flagged). Coverage: volumes 1–16 on the journal's own archive; SCImago-derived coverage 2011–2012, 2014 onward. Article types: original research, reviews (about 15 pages), technical notes (at most 4 printed pages). Indexing: Scopus; Crossref member; UGC-listed per the journal's own statement. DOAJ: no listing confirmed at checking time. OpenAlex S4210211336 at checking: 13,368 works, 2,568 citations, h-index 17. Author charges: could not be verified.

A Note on the Record

This directory's earlier template record for this journal named its publisher only as an internal numeric code and reported an h-index of 21 with coverage 2011–2012, 2014–2026. The coverage span is consistent with the sources checked and is retained. The publisher code is replaced here by the two named imprints the sources actually carry, with their disagreement stated rather than smoothed over, and the h-index is reported as a range across databases with each value attributed, since no single database's figure can honestly stand alone for this journal.

Bottom Line

The International Journal of Drug Delivery Technology is a high-volume Indian pharmaceutics journal with a precisely declared scope, a board-based review process with a stated short timetable, Scopus indexing and an archive that documents a decade and a half of Indian formulation research. Submit to it for fit and for its recognised place in its home academic system — and verify its imprint and charges directly, as this profile has flagged, before you do.